Article · 19 Oct 2026
ArticlePublished 31 Dec 2025
Effects of Methoxyflavone and their Derivatives on Memory Deficits Induced by Scopolamine in Zebrafish Models of Alzheimerandrsquo;s Disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Dementia, predominantly caused by Alzheimer’s disease (60-70% of cases), represents a significant disease burden. As methoxyflavones from Kaempferia parviflora possess AChE-inhibition properties, synthetic methoxyflavones and their derivatives were chosen for their therapeutic potential in established zebrafish neurodegenerative models. Aim: To study the effect of methoxyflavone and its synthetic derivatives in scopolamine-induced memory deficit models of Zebrafish. Methodology: 12 groups of adult Danio rerio (10 fish per tank) were used. A stock solution of all three test drugs (7-methoxyflavone, 7,4’ dimethoxyflavone, and 7,2’,4’ trimethoxyflavone-in doses of 5,10,20 mg), standard Rivastigmine 1.5 mg/kg, and scopolamine 200 μM were prepared & diluted to the desired volume of stock solution in 1 L of system water. Each animal in the designated group was exposed to the drug containing fluid for 60 minutes. Then they were subjected to behavioural models of learning and memory. Results: In the T-maze analysis, 7-methoxyflavone 20 mg/L showed a more extended time spent ratio (1.230 ± 0.207) and a greater total number of entries ratio (1.4261 ± 0.352) in the green arm, which were moderately comparable with the time spent ratio (1.9568 ± 0.228) and the number of entries ratio (2.345 ± 1.013) in the Rivastigmine group. In the light and dark test, zebrafish that received 7-methoxyflavone at doses of 5 mg/L (151 ± 6.548), 10 mg/L (169.1 ± 7.950), and 20 mg/L (176.2 ± 6.442) had significantly increased the time spent in the light chamber in comparison to the Rivastigmine group (220.9 ± 6.154). Conclusion: 7-Methoxyflavone in a dose of 20 mg/L exhibited significant cognitive improvement in scopolamine-induced memory deficit models of Zebrafish. These results position it as a prime candidate for further development and research in the treatment of Alzheimer’s disease dementia.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Drug and Alcohol Research.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Drug and Alcohol Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nithya Panneerselvam”
- BylineArticles whose byline prints “Parimala Kathirvelu”
- BylineArticles whose byline prints “Hemanthkumar Shanmugam”